Clinical trials: Lymph Node Positive
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HER2-positive Breast Cancer, Stage I Breast Cancer
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff…
- Trial name
- ELPIS (NCT04578106)
- Testing
- Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Fundacio Clinic Barcelona
Cervical Cancer, Radiation Toxicity
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00012012
- Testing
- Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
The proposed study is being done to learn more about a particular dose of radiation treatment for breast cancer that is completed in a shorter amount of time than what has traditionally been used to treat breast cancer.
- Trial name
- NCT02700386
- Testing
- Adjuvant Hypofractionated Radiation
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of Colorado, Denver
Cervical Cancer
A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy
Recent studies have shown that the chance of survival among women with advanced cervical cancer is increased when they receive concurrent chemotherapy and radiation to the pelvis.
- Trial name
- NCT00590967
- Testing
- IMRT extended field external beam radiation therapy, Brachytherapy, Cisplatin
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Docetaxel in Node Positive Adjuvant Breast Cancer
The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable…
- Trial name
- TAX316 (NCT00688740)
- Testing
- Docetaxel, 5-fluorouracil, Doxorubicin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 1,491 people
- Sponsor
- Sanofi
Breast Cancer
Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer
This study is being performed to understand the safety of a new radiation treatment called "Multi-Beam Intensity Modulated Radiation Therapy" ( IMRT).
- Trial name
- NCT01127373
- Testing
- Multi-Beam Intensity-Modulated Radiation Therapy, BreastQ questionnaire-
- Where
- 7 sites in United States
- Volunteers
- 116 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00881361
- Testing
- systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy
- Where
- 324 sites in United States
- Volunteers
- 756 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
- Trial name
- NCT00328614
- Testing
- Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the…
- Trial name
- NCT01772472
- Testing
- trastuzumab, trastuzumab emtansine
- Where
- 268 sites in United States, Argentina and 26 more
- Volunteers
- 1,486 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
RATIONALE: Surgery to remove lymph nodes in the armpit in patients with sentinel lymph node micrometastases may remove cancer cells that have spread from tumors in the breast.
- Trial name
- 23-01 (NCT00072293)
- Testing
- Axillary lymph node dissection, No axillary lymph node dissection
- Where
- 31 sites in Australia, Belgium and 8 more
- Volunteers
- 931 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Docetaxel in Breast Cancer
Primary objective : To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer…
- Trial name
- NCT00312208
- Testing
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,299 people
- Sponsor
- Sanofi
Breast Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes.
- Trial name
- NCT00041119
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 527 sites in United States, South Africa
- Volunteers
- 3,871 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
INCB018424 in Patients With Advanced Hematologic Malignancies
The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT00674479
- Testing
- INCB018424
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Male Breast Cancer, Stage II Breast Cancer
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00119262
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Breast Adenocarcinoma
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph…
- Trial name
- NCT00433511
- Testing
- Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 842 sites in United States, Peru and 1 more
- Volunteers
- 4,994 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery.
- Trial name
- NCT00003782
- Testing
- cyclophosphamide, docetaxel, doxorubicin
- Where
- 157 sites in United States, Canada
- Volunteers
- 5,351 people
- Sponsor
- NSABP Foundation Inc